Login to Your Account

$250M Potential

Myriad Gets $100M Upfront in European Deal for Flurizan

By Glen Harris

Friday, May 23, 2008
As its Flurizan product nears what could be a multi-billion dollar market in Alzheimer's disease, Myriad Genetics Inc. launched its global strategy by signing a commercialization deal in Europe with J. Lundbeck AS for $100 million upfront with a potential for $250 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription